Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adverum Biotechnlgs (ADVM)

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 849,332
  • Shares Outstanding, K 64,588
  • Annual Sales, $ 1,610 K
  • Annual Income, $ -72,630 K
  • 60-Month Beta 2.68
  • Price/Sales 2,611.75
  • Price/Cash Flow N/A
  • Price/Book 5.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.39
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -24.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.77 +29.31%
on 01/31/20
16.81 -24.81%
on 02/19/20
+1.19 (+10.39%)
since 01/24/20
3-Month
9.77 +29.31%
on 01/31/20
16.81 -24.81%
on 02/19/20
+1.87 (+17.36%)
since 11/26/19
52-Week
4.04 +212.87%
on 02/28/19
16.81 -24.81%
on 02/19/20
+8.51 (+206.05%)
since 02/26/19

Most Recent Stories

More News
ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc.

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM) Such investors...

ADVM : 12.79 (-2.74%)
Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline

Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADVM : 12.79 (-2.74%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:...

ADVM : 12.79 (-2.74%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:...

ADVM : 12.79 (-2.74%)
ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc.

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM) Such investors...

ADVM : 12.79 (-2.74%)
Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Angela Thedinga has been promoted to...

ADVM : 12.79 (-2.74%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Robert S. Willoughby...

ADVM : 12.79 (-2.74%)
Adverum Biotechnologies to Present at Upcoming Investor Conferences

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at two upcoming investor...

ADVM : 12.79 (-2.74%)
Adverum (ADVM) Alert: Johnson Fistel Launches Investigation into Adverum Biotechnologies; Investors Encouraged to Contact Firm

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Adverum Biotechnologies, Inc. ("Adverum " or the "Company" (NASDAQ: ADVM) on behalf of investors.

ADVM : 12.79 (-2.74%)
Adverum Biotechnologies Announces Closing of $150 Million Public Offering of Common Stock

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten...

ADVM : 12.79 (-2.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade ADVM with:

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

2nd Resistance Point 14.68
1st Resistance Point 13.92
Last Price 12.79
1st Support Level 12.68
2nd Support Level 12.20

See More

52-Week High 16.81
Last Price 12.79
Fibonacci 61.8% 11.93
Fibonacci 50% 10.42
Fibonacci 38.2% 8.92
52-Week Low 4.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar